As on Wednesday, Neurocrine Biosciences, Inc (NASDAQ: NBIX) got off with the flyer as it spiked 2.26% to $121.61, before settling in for the price of $118.92 at the close. Taking a more long-term approach, NBIX posted a 52-week range of $84.23-$157.98.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 24.80%. Meanwhile, its Annual Earning per share during the time was 53.47%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 21.64%. This publicly-traded company’s shares outstanding now amounts to $99.00 million, simultaneously with a float of $96.08 million. The organization now has a market capitalization sitting at $12.04 billion. At the time of writing, stock’s 50-day Moving Average stood at $107.51, while the 200-day Moving Average is $124.75.
Neurocrine Biosciences, Inc (NBIX) Ownership Facts and Figures
Another important factor to analyze is how key investors are playing towards the stock of the Drug Manufacturers – Specialty & Generic industry. Neurocrine Biosciences, Inc’s current insider ownership accounts for 2.89%, in contrast to 93.83% institutional ownership. According to the most recent insider trade that took place on May 05 ’25, this organization’s Director sold 30,000 shares at the rate of 110.20, making the entire transaction reach 3,305,952 in total value, affecting insider ownership by 37,491.
Neurocrine Biosciences, Inc (NBIX) Earnings and Revenue Records
Neurocrine Biosciences, Inc’s EPS increase for this current 12-month fiscal period is 21.64% and is forecasted to reach 5.96 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 34.79% through the next 5 years, which can be compared against the 53.47% growth it accomplished over the previous five years trading on the market.
Neurocrine Biosciences, Inc (NASDAQ: NBIX) Trading Performance Indicators
Let’s observe the current performance indicators for Neurocrine Biosciences, Inc (NBIX). It’s Quick Ratio in the last reported quarter now stands at 3.02. The Stock has managed to achieve an average true range (ATR) of 5.20. Alongside those numbers, its PE Ratio stands at $41.24, and its Beta score is 0.19. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 4.99. Similarly, its price to free cash flow for trailing twelve months is now 24.45.
In the same vein, NBIX’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 2.95, a figure that is expected to reach 0.98 in the next quarter, and analysts are predicting that it will be 5.96 at the market close of one year from today.
Technical Analysis of Neurocrine Biosciences, Inc (NBIX)
Through scrutinizing the latest numbers posted by the [Neurocrine Biosciences, Inc, NBIX], it can be observed that its last 5-days Average volume of 2.5 million was better the volume of 1.49 million, it posted the year before. During the previous 9 days, stock’s Stochastic %D was recorded 70.57% While, its Average True Range was 5.70.
Raw Stochastic average of Neurocrine Biosciences, Inc (NBIX) in the period of the previous 100 days is set at 53.11%, which indicates a major fall in contrast to 71.92% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 32.87% that was lower than 49.37% volatility it exhibited in the past 100-days period.
